A dose escalation study of RO6870810/TEN-10 in patients with acute myeloid leukemia and myelodysplastic syndrome
Gail J. Roboz(Cornell University), Daniel J. DeAngelo(Dana-Farber Cancer Institute), Mark DeMario(BioNTech (United States)), Barbara J. Brennan(Roche (Switzerland)), Evelyne Chesné(Roche (Switzerland)), Eveline Nüesch(University of Bern), Martin Kornacker(Roche (Switzerland)), Katharina Lechner(Roche (Switzerland)), Pinkal Desai(NewYork–Presbyterian Hospital), Ellen K. Ritchie(Cornell University), Laura Brennan(Neurosciences Institute), Sangmin Lee(Korea Advanced Institute of Science and Technology), Eric S. Winer(Providence College)
Cited by 35
Related Papers
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
|Science Translational Medicine|2014|2.5k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k